HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mouthwashes and oral cancer

This article was originally published in The Rose Sheet

Executive Summary

Health-care professionals should not recommend long-term use of mouthwashes containing alcohol in light of findings that the products contribute to oral cancer, according to a peer-reviewed study by MJ McCullough, Melbourne Dental School. In the study, recently published in the Australian Dental Journal, McCullough also holds that mouthrinses containing alcohol should be prescribed by dentists, and their use should be limited to a controlled period of time. "Patients should be provided with written instructions for mouthwash use, and mouthwash use should be restricted to adults for short durations and specific, clearly defined reasons," the researcher says. The study comprised a literature review of epidemiological evidence, supportive in vitro studies and evaluated the mechanism by which alcohol is involved in the development of oral cancer. He noted that some mouthrinses contain significant levels of alcohol and that the ethanol in such formulas degrades mucous membranes in the mouth, increasing cancer risk. In 2003, a study by the American Dental Association concluded mouthwashes are not linked to oral cancer; however, that study was criticized because it was funded by Warner-Lambert, the original marketer of Listerine. In 2003, FDA's Dental Plaque Subcommittee advised that further studies be conducted to determine the relationship between mouthrinses with high alcohol content and oral cancer and that products reveal alcohol content on the principal display panel; those recommendations were included in an FDA advance notice of proposed rulemaking on antigingivitis/antiplaque products (1"The Rose Sheet" June 2, 2003, p. 3)

You may also be interested in...



Potential Cancer Link Scared J&J Off Listerine Marketing Deal – Lawsuit

An oral-care product firm alleges Johnson & Johnson violated a marketing agreement to stifle publicity about a potential link between Listerine and oral cancer.

Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR

FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel